Skip to main content
OpenTrials
Completed

NCT Number: NCT00989157

Effects of Gastric Bypass on Blood Levels of Duloxetine

This study aims to determine the difference, if any, in the pharmacokinetics of duloxetine between patients who are nine to fifteen months post Roux-en-Y Bariatric Surgery and control subjects matched for body mass index (BMI), age and gender.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Neuropsychiatric Research Institute

Fargo, North Dakota, 58103, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects between the ages of 18 and 60 years.
  • Subjects must be of good general health by history and physical exam.
  • Ten experimental subjects 9 to 15 months post bariatric surgery (Roux-en-Y procedure), no BMI requirement.
  • Ten normal control subjects who have met the inclusion criteria and have not received bariatric surgery and who are matched to the surgery subjects according to body mass index, age and sex.
  • Women of child bearing potential must be practicing an accepted method of birth control (barrier method or oral contraceptive) and have a negative pregnancy test at baseline.
  • No contraindications to receiving a single capsule of 60 mg of duloxetine

Exclusion criteria

  • Allergy to duloxetine or any of its constituents.
  • Candidates who are pregnant or nursing
  • Candidates currently receiving any antidepressant.
  • Candidates that are determined to be poor metabolizers for CYP2D6
  • Subjects who smoke or use any nicotine products
  • Candidates currently receiving a medication that interacts with duloxetine.
  • Candidates experiencing clinically significant, unstable neurological, hepatic, renal or cardiovascular disease.
  • Candidates experiencing or with a history of vomiting or diarrhea associated with bariatric surgery
  • Candidates currently or with a past history of meeting DSM-IV diagnostic criteria for schizophrenia, schizoaffective disorder, bipolar disorder.
  • Candidates who have participated in an investigational drug study in past 30 days.
  • Candidates who meet DSM-IV diagnostic criteria for drug/alcohol abuse or dependency or who have a history of drug/alcohol abuse or dependency.

Treatment and study plan

Duloxetine

Drug

Single dose of 60 mg of duloxetine

Other names: Cymbalta

Primary outcomes

  1. Cmax

    Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.25, 2.5, 3.5, 4.5, 6.5, 8.5, 10.5, 24, 48. 72

    The difference, if any, in the pharmacokinetics parameters (Cmax) of duloxetine between patients who are nine to fifteen months post Roux-en-Y Bariatric Surgery and control subjects matched for BMI, age and gender.

  2. Tmax

    Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.25, 2.5, 3.5, 4.5, 6.5, 8.5, 10.5, 24, 48. 72

    Time to maximum plasma concentration

  3. AUCo-inf,

    Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.25, 2.5, 3.5, 4.5, 6.5, 8.5, 10.5, 24, 48. 72

    Area under the plasma concentration time curve

  4. T1/2

    Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.25, 2.5, 3.5, 4.5, 6.5, 8.5, 10.5, 24, 48. 72

    Half life

Secondary outcomes

  1. Emesis

    Time frame: 4 days

    episodes of emesis.

Sponsors and collaborators

Lead sponsor

Neuropsychiatric Research Institute, Fargo, North Dakota

Other

Collaborators

  • Eli Lilly and Company
  • University of North Dakota

Registry information

Official study title

A Preliminary Comparison of the Effect of Roux-en-Y Bariatric Surgery on Blood Levels of Duloxetine

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Oct 2, 2009
Registry last updated
Aug 11, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.